Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.50 USD
-0.06 (-10.15%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.50 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 61 - 80 ( 322 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STEADFAST Program Could Open Platform to Multiple Blockbuster Autoimmune Disease Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Broad Progress Across Internal and External Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Anticipation Building Towards Key Clinical Catalysts by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAAR of Pack on Track for Initial In-Human Data Late in 2021; Establishing Fabry Disease Market Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Fabry Program on Track to Generate Initial In-Human Data By 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials: Steady Progress Toward Key Catalysts & Year-End Inflection Point
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT Abstracts Highlight Preclinical Neurodegenerative- Partnered Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from Virtual NDR on March 25, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Designation Granted to BIVV003/SCD by EMA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expect the Internal Pipeline to Shine in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY20 Financials: Pipeline Progress Points to Fabry data by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flexible Fingers Forming Broad Pipeline in Multiple Tissues; Transferring Coverage With a Buy and $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Long-Term SB-525/Hemo A Ph1/2 Data Presented at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Pipeline Taking Shape; HemA at ASH; Initial Fabry Data by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L